Import from "@/components/mdx"

Farxiga and Rosuvastatin Interaction: What Women Need to Know

Can You Take Farxiga with Rosuvastatin?

Yes, you can take Farxiga (dapagliflozin) and rosuvastatin together. The FDA prescribing information for dapagliflozin does not list rosuvastatin as a drug with a clinically meaningful pharmacokinetic interaction, and the same is true for rosuvastatin's labeling. Neither drug shares a primary metabolic pathway that would cause one to raise or lower the blood level of the other.

"no interaction" does not mean "no monitoring needed." Both medications affect the cardiovascular and metabolic system, and every woman's clinical picture, kidney function, and statin tolerance should be reviewed by her prescriber before starting or continuing either drug.

Why Women Are Often Prescribed Both

Women with type 2 diabetes carry a proportionally higher relative cardiovascular risk than men with the same diagnosis, according to a 2014 meta-analysis in The Lancet Diabetes & Endocrinology covering over 850,000 participants. Statin therapy to lower LDL-cholesterol and an SGLT2 inhibitor to protect the heart and kidneys are therefore a logical pairing.

PCOS, which affects approximately 8 to 13 percent of women of reproductive age, raises dyslipidemia and insulin-resistance risk simultaneously, often prompting exactly this combination. Perimenopause and post-menopause bring a further shift in LDL and triglyceride levels as estrogen declines, increasing the population of women who need both a statin and an SGLT2 inhibitor.

How Each Drug Is Metabolized (and Why the Pathways Do Not Collide)

Understanding the metabolism of each drug explains why the combination is safe from a pharmacokinetic standpoint.

Dapagliflozin (Farxiga)

Dapagliflozin is metabolized primarily by UDP-glucuronosyltransferase 1A9 (UGT1A9) in the liver and kidney. It is not a substrate of CYP3A4, CYP2C9, or CYP2D6, the enzymes most commonly involved in clinically significant drug interactions. It is a weak substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but at therapeutic doses these transporters do not produce meaningful changes in exposure.

Renal excretion contributes to elimination, which is why dose adjustments are needed when estimated glomerular filtration rate (eGFR) falls. For type 2 diabetes, dapagliflozin is not recommended when eGFR is persistently below 45 mL/min/1.73 m²; for CKD indication, it may be continued down to eGFR 25 mL/min/1.73 m² per updated labeling.

Rosuvastatin

Rosuvastatin is minimally metabolized by CYP2C9 (approximately 10% of a dose). Its primary pharmacokinetic vulnerability is uptake by the hepatic organic anion-transporting polypeptide transporters OATP1B1 and OATP1B3. Drugs that inhibit these transporters, such as cyclosporine or certain HIV protease inhibitors, can dramatically raise rosuvastatin plasma concentrations and increase myopathy risk.

Dapagliflozin does not inhibit OATP1B1 or OATP1B3 at clinically relevant concentrations. It is also not a meaningful inhibitor of CYP2C9. This is the mechanistic basis for the absence of an interaction between these two drugs.

What the FDA Labels Actually Say

The dapagliflozin label includes a dedicated drug-interaction section listing agents studied in formal pharmacokinetic crossover trials. Rosuvastatin is not listed as causing a change in dapagliflozin exposure, and dapagliflozin is not listed on the rosuvastatin label as a perpetrator or victim of a meaningful interaction. This mutual absence reflects the differing metabolic profiles described above.

Pharmacodynamic Considerations: Do the Drugs Interact on the Body's Systems?

Pharmacokinetics covers what the body does to the drug. Pharmacodynamics covers what the drug does to the body. Even when two drugs do not alter each other's blood levels, they can still interact at the level of physiology.

Blood Pressure and Volume Effects

Dapagliflozin causes mild osmotic diuresis and sodium loss, producing a mean systolic blood pressure reduction of approximately 3 to 5 mmHg in trials. Rosuvastatin has no meaningful blood-pressure effect. There is no additive hypotension concern between these two agents.

Blood Glucose

Rosuvastatin, like other statins, carries a small but real risk of raising fasting glucose and contributing to new-onset type 2 diabetes. The JUPITER trial (rosuvastatin 20 mg vs placebo, n = 17,802) found a 27% higher rate of physician-reported diabetes in the rosuvastatin arm. Dapagliflozin lowers blood glucose. In clinical practice these two opposing effects do not produce a problematic swing, but your prescriber should track HbA1c when both are started or when the rosuvastatin dose changes significantly.

Kidney Function

Both drugs can affect renal parameters. Dapagliflozin causes an initial modest drop in eGFR that is generally reversible and considered hemodynamic rather than structural. In women with pre-existing CKD or a single functioning kidney, this should be factored into the choice of statin dose, since rosuvastatin exposure rises as kidney function falls. The rosuvastatin label recommends a starting dose of 5 mg daily in patients with severe renal impairment (CrCl <30 mL/min) who are not on hemodialysis.

Muscle Safety

Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 29 percent of statin users in real-world studies, with some evidence that women report myalgia at slightly higher rates than men. Dapagliflozin does not cause myopathy and has no known mechanism that would amplify rosuvastatin's muscle risk. Still, any woman on rosuvastatin should know to report unexplained muscle pain, weakness, or brown-colored urine to her provider promptly, regardless of whether she also takes Farxiga.

Sex-Specific Physiology: How Being a Woman Changes This Picture

Most major drug-interaction studies enroll a majority of male participants, and dapagliflozin's own pharmacokinetic analyses are no exception. A WomanRx clinical framework for evaluating this combination across female life stages:

Reproductive Years (Ages 18-40, Including PCOS)

Women with PCOS often have insulin resistance, elevated LDL, and early cardiovascular risk markers. SGLT2 inhibitors are being studied in PCOS for their metabolic benefits beyond glycemic control. If a clinician prescribes dapagliflozin alongside a statin for a woman in her reproductive years, contraception must be discussed (see Pregnancy and Lactation section below).

Regarding pharmacokinetics, the FDA population PK analysis of dapagliflozin found that body weight, not sex, was the stronger predictor of apparent clearance. Women on average have lower body weight than men in trials, which can translate to modestly higher drug exposure at a fixed dose, though this has not been found clinically significant for dapagliflozin's standard 10 mg dose.

Perimenopause (Typically Ages 45-55)

The estrogen decline of perimenopause triggers a shift toward higher LDL-cholesterol, lower HDL, and rising triglycerides. Many women in this life stage are prescribed their first statin. Concurrently, insulin sensitivity worsens, raising the risk of type 2 diabetes even in women who were previously metabolically healthy.

The DECLARE-TIMI 58 trial evaluated dapagliflozin in 17,160 adults with type 2 diabetes or multiple cardiovascular risk factors. Women represented approximately 37 percent of the cohort, and the cardiovascular and renal benefits were consistent across sex subgroups, though the trial was not powered to draw definitive conclusions in women separately.

For the perimenopausal woman on both rosuvastatin and dapagliflozin, the main monitoring points are blood glucose (for statin-related dysglycemia), eGFR (for any dapagliflozin-related hemodynamic change), and muscle symptoms.

Post-Menopause

Post-menopausal women have the highest absolute cardiovascular risk among all female life stages and are the group most likely to be on long-term statin therapy. The combination of dapagliflozin for heart failure or CKD and rosuvastatin for cardiovascular risk reduction is therefore most prevalent in this group.

The DAPA-HF trial (n = 4,744) showed that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo in patients with heart failure with reduced ejection fraction. Women made up 23 percent of the DAPA-HF population, a representation gap that the women's-health community has repeatedly flagged. The directional benefit in women was consistent, but confidence intervals were wide due to small numbers.

Who This Combination Is Right For, and Who Should Be Cautious

Likely a Good Fit

• Women with type 2 diabetes and elevated LDL who need both glycemic control and lipid management
• Women with established cardiovascular disease or high cardiovascular risk, particularly after menopause
• Women with CKD (eGFR 25 to 75 mL/min/1.73 m²) who need nephroprotection and statin therapy simultaneously
• Women with PCOS and dyslipidemia who are already using or being considered for dapagliflozin for its metabolic effects

Use With More Caution or Reassess

• Women with eGFR persistently <25 mL/min/1.73 m²: dapagliflozin's renal benefits diminish, and rosuvastatin dose should be adjusted for kidney impairment
• Women with a personal or family history of statin-induced myopathy: the standard rosuvastatin precautions apply; co-prescribing dapagliflozin does not add muscle risk, but baseline creatine kinase testing may be warranted
• Women taking medications that inhibit OATP1B1 (such as cyclosporine, used in autoimmune conditions more common in women), which would raise rosuvastatin levels independently of dapagliflozin
• Women with recurrent urinary tract infections: dapagliflozin increases glucosuria, raising UTI risk; this is unrelated to rosuvastatin but relevant to the overall decision

Pregnancy, Lactation, and Contraception: A Required Conversation

Both dapagliflozin and rosuvastatin are contraindicated during pregnancy. This is one of the most clinically important aspects of prescribing this combination to women of reproductive age.

Dapagliflozin in Pregnancy

Dapagliflozin is FDA Pregnancy Category not assigned under the new labeling system, but the label states: "Dapagliflozin is not recommended during the second and third trimesters of pregnancy". Animal studies showed renal adverse effects in offspring exposed during periods of nephrogenesis, which in humans corresponds to the second and third trimesters. There are no adequate and well-controlled human studies. The drug should be stopped as soon as pregnancy is confirmed.

Lactation: It is not known whether dapagliflozin is excreted in human breast milk. Animal data show presence in milk. Because of the potential for serious adverse effects in a nursing infant, the label advises against use during breastfeeding.

Rosuvastatin in Pregnancy

Rosuvastatin is contraindicated in pregnancy. The rosuvastatin prescribing information states the drug should be discontinued immediately when pregnancy is recognized, consistent with the ACOG guidance that statin therapy should be avoided in pregnancy due to potential fetal harm. Cholesterol is needed for normal fetal development, and statin-induced reduction of mevalonate-pathway products may interfere with this process. Human case reports and registry data, while limited, include cases of structural fetal abnormalities associated with first-trimester statin use.

Lactation: Rosuvastatin is present in rat breast milk. No adequate human lactation studies exist. Because of the lipid-lowering mechanism and the theoretical risk of disrupting infant lipid metabolism, rosuvastatin is not recommended during breastfeeding.

Contraception Guidance

Any woman of reproductive potential who is prescribed both dapagliflozin and rosuvastatin should use effective contraception for the duration of treatment with either drug. Given that both agents are chronic therapies, this means ongoing, reliable contraception, not just barrier methods used intermittently. A discussion with your prescriber about the most appropriate contraceptive method for your life stage and medical history is a direct clinical necessity, not an optional add-on.

Monitoring Plan When Taking Farxiga and Rosuvastatin Together

Your prescriber will likely track the following at baseline and periodically thereafter:

| Parameter | Frequency | Reason | |---|---|---| | eGFR and serum creatinine | At baseline, 4-8 weeks after starting dapagliflozin, then every 3-6 months | Dapagliflozin hemodynamic eGFR dip; rosuvastatin dose adjustment if eGFR falls | | HbA1c and fasting glucose | Every 3 months initially, then every 6 months | Statin-associated dysglycemia; glycemic response to dapagliflozin | | Lipid panel | At baseline, 6-12 weeks after statin initiation or dose change, then annually | LDL target attainment | | Creatine kinase | At baseline if muscle risk factors present; if SAMS symptoms develop | Statin myopathy surveillance | | Urinalysis / UTI symptoms | As clinically indicated | Dapagliflozin-related glucosuria and UTI risk | | Blood pressure | Routine | Modest BP-lowering effect of dapagliflozin |

What the Evidence Gap Means for You

Women have been under-represented in the key trials for both drugs. In DECLARE-TIMI 58, 37 percent of enrolled participants were women. In the major statin cardiovascular outcome trials, women typically represent 20 to 30 percent of participants. This means the interaction data, the efficacy data, and the dose-optimization data are all primarily derived from male-majority populations.

What is directly studied: the formal pharmacokinetic interaction studies for dapagliflozin used mixed-sex cohorts; none have specifically studied the combination in women with PCOS, perimenopausal women, or post-menopausal women as primary populations.

What is extrapolated: the conclusion that the pharmacokinetic interaction is absent in women is extrapolated from the established metabolic profiles of each drug and from mixed-sex PK data. This extrapolation is scientifically reasonable but not women-specific.

If you are a woman who has experienced unexpected side effects, unusual glucose fluctuations, or muscle symptoms while on both drugs, report them to your prescriber and ask whether a formal medication review is warranted. Real-world pharmacovigilance in women is one way the evidence gap closes over time.

Frequently Asked Questions